Cabergoline
Mostrando 1-12 de 16 artigos, teses e dissertações.
-
1. Como deve ser feita a inibição da lactação?
Métodos não farmacológicos:
– Evitar a sucção e outras formas de estímulo.
– Aplicar compressas frias durante 10 minutos, 4 vezes ao dia.
– Fazer enfaixamento compressivo, com ataduras elásticas por volta de 7 a 10 dias após o parto, com cuidado para não restringir os movimentos respiratórios ou causar desconforto materno
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
2. Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature
ABSTRACT Objective: It is reported that adding cabergoline to somatostatin analog (SSA) normalizes IGF-1 levels approximately in one-third of patients with acromegaly. We investigated the effect of combination therapy and potential predictors of response in patients with acromegaly who do not respond to SSA therapy alone. Subjects and methods: Fifty acrome
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
3. Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience
ABSTRACT Objective: To evaluate the response to cabergoline (CBG) treatment in patients with non-functioning pituitary adenomas (NFPA). Subjects and methods: Retrospective, single tertiary care center study. A total of 44 patients were treated with 3 mg/week of CBG, 32 after surgical treatment (transsphenoidal surgery [TSS] in 27 and TC in 5 patients) and
Archives of Endocrinology and Metabolism. Publicado em: 2022
-
4. Patient's point of view on the diagnosis, treatment, and follow-up in acromegaly: single-center study from a tertiary center
SUMMARY OBJECTIVE: We aimed to evaluate the awareness and perspectives of acromegaly patients in the diagnosis and treatment processes and to evaluate basic clinical and demographic features. METHODS: This cross-sectional study was conducted at the Endocrinology Department of Yildirim Beyazit University between March 2019 and April 2020. A total of 58 acro
Revista da Associação Médica Brasileira. Publicado em: 2022
-
5. Pegvisomant in acromegaly: a multicenter real-life study in Argentina
ABSTRACT Objective To describe the long term safety and efficacy of pegvisomant (PEGV), and the predictors of treatment response in patients with acromegaly in the real life setting. Subjects and methods We retrospectively reviewed the clinical, hormonal and radiological data of acromegalic patients treated with PEGV in 17 Argentine centers. Results Se
Arch. Endocrinol. Metab.. Publicado em: 22/08/2019
-
6. Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia)
ABSTRACT Introduction Gigantism is a rare pediatric disease characterized by increased production of growth hormone (GH) before epiphyseal closure, that manifests clinically as tall stature, musculoskeletal abnormalities, and multiple comorbidities. Materials and methods Case series of 6 male patients with gigantism evaluated at the Endocrinology Service
Arch. Endocrinol. Metab.. Publicado em: 29/07/2019
-
7. Brazilian multicenter study on pegvisomant treatment in acromegaly
ABSTRACT Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were include
Arch. Endocrinol. Metab.. Publicado em: 29/07/2019
-
8. Controversial issues in the management of hyperprolactinemia and prolactinomas – An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
ABSTRACT Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represent an important cause of hypogonadism and infertility in both sexes. The magnitude of prolactin (PRL) elevation can be useful in determining the etiology of hyperprolactinemia. Indeed, PRL levels > 250 ng/mL are highly suggestive of the presence of a p
Arch. Endocrinol. Metab.. Publicado em: 2018-03
-
9. A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism
ABSTRACT The treatment objectives for a patient with Cushing's disease (CD) are remission of hypercortisolism, adequate management of co-morbidities, restoration of the hypothalamic-pituitary-adrenal axis, preservation of fertility and pituitary function, and improvement of visual defects in cases of macroadenomas with suprasellar extension. Transsphenoidal
Arch. Endocrinol. Metab.. Publicado em: 2018-02
-
10. Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report
OBJECTIVE: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS: Cross-sectional and retrospective study of thirty cases treated over a period of two decades. RESULTS: 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphen
Clinics. Publicado em: 2017-04
-
11. Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
ABSTRACT Objective To describe the safety and efficacy of pegvisomant therapy and the predictors of treatment response in acromegaly patients at a single tertiary reference center in Brazil. Materials and methods We retrospectively reviewed the clinical, hormonal and radiological data of acromegaly patients treated with pegvisomant in our center. We also
Arch. Endocrinol. Metab.. Publicado em: 10/10/2016
-
12. Mean platelet volume in patients with prolactinoma
ABSTRACT Objective Prolactin is a multifunctional pituitary hormone. The effect of prolactin on platelet activation is not well understood. Prolactinomas are the most common type of pituitary adenomas, and they are medically responsive to dopamine agonists. Mean platelet volume (MPV) is a marker of platelet function and activation. The aim of this study wa
Arch. Endocrinol. Metab.. Publicado em: 16/02/2016